Presbia, which sells a surgically implanted lens to correct age-related vision loss, filed on Thursday with the SEC to raise up to $90 million in an initial public offering. It targets the common vision disorder presbyopia, which affects 1.8 billion people worldwide. The Irvine, CA-based company, which was founded in 2007, plans to list on the NASDAQ under the symbol LENS. Jefferies is the sole bookrunner on the deal. No pricing terms were disclosed.
